Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: Cancer Discov. 2012 Jan 1;2(1):56–67. doi: 10.1158/2159-8290.CD-11-0170

Figure 2.

Figure 2

AKT dependence of ovarian cancer cell lines. A, IC50/90 values for the AKT-1/2 inhibitor (AKTi-1/2) and panAKT-1/2/3 inhibitor (MK2206) were calculated following treatment with 0–10 µM of each inhibitor for 5 days. Drug concentrations are represented by color block gradations from dark red (0–0.3 µM) to bright red (0.3–1.7 µM), dark pink (1.7–3 µM), pale pink (3–10 µM), and white (>10 µM). Cells with detectable AKT3 expression are indicated by black boxes. Cell lines are colored based upon the presence of PI3K/AKT (red) or RAS/RAF-pathway (blue) alterations and RB1 loss (green) as in Fig. 1B. B, Cells were treated for 0–24 h with AKTi-1/2 or MK2206 (2 µM) and lysates immunoblotted for p-AKT S473 and total AKT. C, Day 5 dose response plots of three representative cell lines (IGROV-1, hypersensitive to AKT inhibition, red; OVCAR-5, heightened sensitivity to pan-AKT inhibition, blue; SKOV-433, resistant to AKT inhibition, green).